UMMS Affiliation

Department of Dermatology

Publication Date

2021-06-02

Document Type

Letter to the Editor

Disciplines

Dermatology | Skin and Connective Tissue Diseases

Abstract

To the Editor: Vitiligo is a chronic autoimmune disease resulting in patches of depigmented skin and reduced quality of life. In a randomized, dose-ranging phase 2 study (NCT03099304) in 157 adult patients, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib cream produced substantial repigmentation of facial and total body vitiligo lesions after 24 weeks, with continued improvement through week 52, and was well tolerated.3 Here, we present treatment response subanalyses from the phase 2 trial.

Keywords

vitiligo, ruxolitinib

Rights and Permissions

Copyright 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/.

DOI of Published Version

10.1016/j.jaad.2021.05.047

Source

Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2021 Jun 2:S0190-9622(21)01043-4. doi: 10.1016/j.jaad.2021.05.047. Epub ahead of print. PMID: 34089797. Link to article on publisher's site

Journal/Book/Conference Title

Journal of the American Academy of Dermatology

Related Resources

Link to Article in PubMed

PubMed ID

34089797

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS